Hasnain Faheem's Form 4 filing
Kura Oncology, Inc. (KURA) · filed Dec 10, 2025
- Accession no.
- 0001193125-25-314154
- Filed
- Dec 10, 2025
- Trade date
- Dec 9, 2025
- Filing delay
- 1 day
- Rule 10b5-1 plan
- Not checked
This filing lists 2 non-derivative transactions. Open-market sales total $109.8K. It was filed 1 day after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Hasnain FaheemCIK 0001352620 | Director |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Dec 9, 2025 | Common Stock | MOption exerciseAcquired | +10,000 | $3.12 | +$31,200 | 33,983 | Direct | |
| Dec 9, 2025 | Common Stock | SSaleDisposed | −10,000 | $10.98F2 | −$109,800 | 23,983 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F2
This transaction was executed in multiple trades at prices ranging from $10.60 to $11.53. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
Referenced by the price of 1 transaction in Table I.